Saturday 17 October 2026
Export IOBTQ’s income statement to Excel — free account
IO Biotech, Inc.
IOBTQ Healthcare Biotechnology
In the quarter to September 2025, EPS grew 63.9% and free cash flow grew 11.2%, each against the same quarter a year earlier.
0.00
0.00
NaN
Follow IOBTQ
| Older periods | Dec '24 | Mar '25 | Jun '25 | Sep '25 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(106.00%) | (138.78%) | (212.51%) | (240.48%) | |
| (87.44%) | (113.23%) | (135.23%) | (136.03%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(207.13%) | (399.04%) | (528.22%) | (463.43%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.25) | (1.22) | (1.27) | (1.21) | |
Free Cash Flow |
(82.39) | (80.55) | (83.40) | (81.06) | |
Capital Expenditures |
(0.04) | (0.06) | (0.07) | (0.07) | |
| Other line items | |||||
Cash ROIC |
(76.97%) | (126.83%) | (228.85%) | (168.05%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.02 | 0.01 | 0.01 | (0.01) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | — | (23.70) | (22.77) | |
Operating CF/Net income |
0.86 | 0.82 | 0.80 | 0.92 | |
Depreciation/Fixed assets |
0.40 | 0.41 | 0.42 | 0.46 | |
Capex/Depreciation |
(0.17) | (0.24) | (0.30) | (0.28) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.25) | (1.22) | (1.26) | (1.21) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates